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Abstract
RN181, a RING finger domain-containing protein, is an E3 ubiquitin ligase. However, its biological function
and clinical significance in cancer biology are obscure. Here, we report that RN181 expression is significantly
down-regulated in 165 tumour tissues of gastric carcinoma (GC) versus adjacent non-tumour tissues, and inversely
associated with tumour differentiation, tumour size, clinical stage, and patient’s overall survival. Alterations of
RN181 expression in GC cells by retrovirus-transduced up-regulation and down-regulation demonstrated that
RN181 functions as a tumour suppressor to inhibit growth of GC in both in vitro culture and in vivo animal
models by decreasing tumour cell proliferation and increasing tumour cell apoptosis. Cell cycle analysis revealed
that RN181 controls the cell cycle transition from G1 to S phase. Mechanistic studies demonstrated that RN181
inhibits ERK/MAPK signalling, thereby regulating the activity of cyclin D1–CDK4, and consequently controlling
progression in the cell cycle from G1 to S phase. Restoring CDK4 in GC cells rescued the inhibitory phenotype
produced by RN181 in vitro and in vivo, suggesting a dominant role of CDK4 in control of the tumour growth
by RN181. Importantly, RN181 expression is inversely correlated with the expression of cyclin D1 and CDK4 in
GC clinical samples, substantiating the role of the RN181–cyclin D1/CDK4 pathway in control of the tumour
growth of GC. Our results provide new insights into the pathogenesis and development of GC and rationale for
developing novel intervention strategies against GC by disruption of ERK/MAPK–cyclin D1/CDK4 signalling. In
addition, RN181 may serve as a novel biomarker for predicting clinical outcome of GC.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Gastric adenocarcinoma (gastric cancer, GC) is the fifth
most common cancer and the third leading cause of can-
cer mortality worldwide [1]. In China, however, GC is
the second most common cancer and the second lead-
ing cause of cancer death, having estimated numbers of
679 100 new cases and 498 000 deaths in 2015 [2]. Most
GC patients present with advanced or metastatic disease
in clinics and are treated only by palliative chemother-
apy, with an overall 5-year survival around 5–20% and a
median overall survival of 11–12months [3]. In addition
to standard perioperative chemotherapy or postoperative
chemoradiation [4–6], targeted therapy, which targets
specific molecules and disrupts the activity of a spe-
cific oncogenic signalling pathway, has emerged as a
promising therapeutic strategy. Recently, a randomised
phase 3 trial for the first-line treatment of HER2-positive
advanced GC showed that trastuzumab, a humanised
monoclonal antibody targeting HER2, when combined
with standard chemotherapy, significantly improves an
overall survival of GC patients from 11.1 months to
13.8 months [3]. Unfortunately, only 7–34% of GC
patients are HER2-positive [3,7] and thus clinical appli-
cation of trastuzumab is highly restricted. Therefore, it
is imperative that identification of new targets will help
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to understand the molecular mechanisms of pathogen-
esis and develop a novel targeted therapy or biomarker
for evaluating the therapeutic efficacy or predicting the
prognosis of GC patients [8].
RN181 (also named RNF181 or HSPC238) is a mem-
ber of the really interesting new gene (RING) finger
protein family whose members are well recognised in
protein dimerisation and protein–protein interaction and
possess ubiquitin ligase activities [9]. It was reported
that in platelets, RN181 interacts with the cytoplas-
mic regulatory domain of integrin αIIbβ3 and exhibits
E3 ubiquitin ligase activity for auto-ubiquitination [10].
However, the physiological substrates and biological
functions of RN181 in cancer biology are obscure. We
have been interested in RING finger ubiquitin ligases in
cancer biology and clinical significance. In this paper,
we report that RN181 is significantly down-regulated
in GC clinical samples and is closely associated with
some clinicopathological features and patient’s overall
survival. Up-regulation and down-regulation of RN181
demonstrated that RN181 functions as a tumour sup-
pressor that controls the tumour growth of GC. Mech-
anistic studies revealed that RN181 controls tumour
growth through induction of cell cycle arrest at theG1–S
phase transition by inhibition of ERK/MAPK signalling




The lentivirus packaging cell line (GP2-293) and GC
cell lines (AGS, MKN28, and MKN45) were pur-
chased from and authenticated by the Shanghai Insti-
tutes for Biological Sciences (Shanghai, PR China). All
cell lines were cultured in Dulbecco’s modified Eagle’s
medium (Gibco, Grand Island, NY, USA) supplemented
with 10% fetal bovine serum, 100U/ml penicillin, and
100 μg/ml streptomycin, and maintained at 37∘C with
5% CO2.
Patients and tissue samples
GC clinical samples (HStm-Ade167Sur and HStm-
Ade180Sur) containing clinicopathological information
were purchased from Shanghai Outdo Biotech Co,
Ltd (http://www.superchip.com.cn/). One hundred and
sixty-five GC tissue specimens paired with adjacent
non-tumour gastric tissues were used for immuno-
histochemical (IHC) studies. Patients’ consent and
approval from local Ethics Committee were obtained
for research in use of clinical materials. The patients
included 118 males and 47 females, with a median
age of 65 years (range 34–84 years) (supplementary
material, Table S1). Clinical stages were according
to the 7th edition of the AJCC Cancer Staging Man-
ual [11]. Another cohort (HStm-Ade150CS-01) of
clinical samples, consisting of 75 pairs of GC and
adjacent non-tumour tissues, was used for analysis of
the expression correlation between RN181, cyclin D1,
and CDK4.
Tumour xenografts
BALB/c female nude mice 4–5 weeks of age were pur-
chased from the Experimental Animal Center, Southern
Medical University (Guangzhou, PR China) and main-
tained under standard pathogen-free conditions. Tumour
xenografts were performed as described previously [12].
The left flank of each mouse was implanted with con-
trol tumour cells, while the right side was injected with
the test tumour cells. Each group contained six mice.
Tumour growth was monitored by measuring tumour
length andwidthwith callipers. Tumour volumewas cal-
culated with the formula [length × width2 × (π/6)] [13].
All experimental procedures were approved by the Eth-
ical Committee of Southern Medical University.
Immunohistochemical staining and scoring
IHC staining was performed as described previously
[12]. Histopathological features of stained tumour were
assessed by two researchers who were blinded to the
patient’s clinical characteristics. The intensity of RN181
immunostaining of GC tissues was scored as negative
(0), weak (1), medium (2) or strong (3). The extent of
staining, defined as the per cent of positive staining cells,
was scored as 1 (≤ 10%), 2 (11–50%), 3 (51–75%) or 4
(> 75%). An overall expression score for statistical anal-
ysis, ranging from 0 to 12, was calculated bymultiplying
the score of intensity and that of extent. The final stain-
ing score was presented as low (overall score of ≤ 3) or
high (overall score of> 3). Nuclear localisation of cyclin
D1 or CDK4 was quantified by counting approximately
500 stained cells under 400× magnification.
IHC staining of anti-RN181 (1:300 dilution),
anti-Ki67 (1:200 dilution), anti-activated caspase 3
(1:100 dilution), anti-p21 (1:400 dilution), anti-cyclin
D1 (1:400 dilution), anti-CDK4 (1:400 dilution)
and anti-pERK1/2 (Thr202/Tyr204) (1:400 dilution)
(#4370S; Cell Signaling, Danvers, MA, USA) for
xenograft tumour sections was performed and scored as
described above.
Statistics
SPSS 13.0 software (SPSS Inc, Chicago, IL, USA)
was used. The analysis of variance (ANOVA) test was
used to compare mean values among three or more
groups, whereas independent-sample Student’s t-test
was used to compare two groups with normal distri-
bution data. The data normality was verified using the
Kolmogorov–Smirnov test. For non-normal distribution
data, the Mann–Whitney test was used for two-group
comparisons, while the Jonckheere–Terpstra test was
used to compare more than two groups. Sample-paired
t-tests were employed to analyse the expression of
RN181 in paired clinical samples and xenograft tumour
sizes. Kaplan–Meier plots and the log-rank test were
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used for analysis of overall survival data. Univariate and
multivariate survival analyses were conducted using the
Cox proportional hazards regression model. The Pear-
son correlation test was used to analyse the correlation
between the expression of two proteins. Statistical sig-
nificance is indicated in the figures by an asterisk where
p < 0.05 and by two asterisks where p < 0.01.
Results
RN181 is down-regulated and associated
with overall survival of GC patients
We examined the expression of RN181 in a cohort of 165
pairs of GC and adjacent non-tumour tissues by IHC
(Figure 1A and supplementary material, Figure S1).
Quantitative analysis by scoring the staining showed
that RN181 was significantly down-regulated in tumour
tissues versus adjacent tissues (2.19± 2.10 versus
5.94± 4.22) (p < 0.01) (Figure 1B). Clinicopathologi-
cal analyses demonstrated that the expression of RN181
was significantly associated with tumour differentiation
(Z =−2.045, p = 0.041), tumour size (Z =−2.484,
p = 0.013), and clinical stage (Z =−2.765, p = 0.006)
but not with patient’s gender or age (supplementary
material, Table S1). Decreased expression of RN181
was frequently observed in tumours that were poorly
differentiated, had a larger tumour size, and were in
a late clinical stage. Kaplan–Meier analysis revealed
that expression of RN181 was significantly associated
with overall survival of GC patients (p = 0.004), show-
ing a median survival of more than 70.0 months in the
RN181-high expression group versus 31.9 months in the
RN181-low expression group (Figure 1C). Univariate
Cox regression analysis showed that many parameters
including age, tumour size, metastasis, and clinical stage
were significantly correlated with patient overall sur-
vival (Table 1). Multivariate analysis demonstrated that
RN181 expression has a prognostic role (HR= 2.337,
95% CI 1.238–4.422, p = 0.009). Thus, the results sug-
gest that down-regulation of RN181 may be involved
in the tumour development of GC and serve as an
independent poor prognostic biomarker for GC patients.
RN181 suppresses tumour growth of GC in vitro
and in vivo
We up-regulated the expression of RN181 in GC cells
by retrovirus-mediated transduction (Figure 2A). Cell
proliferation assays demonstrated that up-regulation
of RN181 significantly inhibited the AGS growth
(AGS-RN181 versus AGS-RV control, p < 0.01)
(Figure 2B). Colony formation assays showed that
up-regulation of RN181 significantly reduced the num-
ber of colonies formed by AGS cells (AGS-RN181
versus AGS-RV control, p < 0.01) (Figure 2C). Con-
sistently, down-regulation of endogenous RN181 by
transduction of shRNA-containing viruses significantly
increased the proliferation and colony formation of AGS
cells (AGS-KD versus AGS-NC control, p < 0.01). Sim-
ilar results were obtained fromMKN28 andMKN45 cell
lines in which RN181 expression was down-regulated
(supplementary material, Figure S2A–C).
We then implanted the GC cells into nude mice.
Up-regulation of RN181 significantly inhibited
the tumour growth (AGS-RN181 versus AGS-RV,
p < 0.01), while down-regulation of RN181 dramati-
cally promoted the tumour growth of AGS (AGS-KD
versus AGS-NC, p < 0.01) (Figure 2D). Similar results
were obtained from the xenografted tumour of MKN28
cells in which RN181 expression was modulated
(supplementary material, Figure S2D).
IHC staining of tumour sections confirmed the
up-regulation (AGS-RN181 versus AGS-RV, p < 0.01)
and down-regulation of RN181 (AGS-KD versus
AGS-NC, p < 0.01) (Figure 2E) in GC tumours.
Tumour cell proliferation in xenograft tumours was
significantly decreased, as revealed by IHC for Ki67
(AGS-RN181 versus AGS-RV, p < 0.05), whereas
tumour cell apoptosis was significantly increased,
as demonstrated by anti-activated caspase 3 staining
(AGS-RN181 versus AGS-RV, p < 0.01). In agree-
ment with the up-regulation results, down-regulation
of RN181 increased tumour cell proliferation and
decreased tumour cell apoptosis in xenograft tumours
(AGS-KD versus AGS-NC, p < 0.05) and in AGS cells
cultured in vitro (supplementary material, Figure S3).
Taken together, the results suggest that RN181 func-
tions as a tumour suppressor in the stomach to control
the tumour growth of GC by decreasing tumour cell
proliferation and increasing tumour cell apoptosis.
RN181 controls cell cycle progression of GC
We performed cell cycle analyses by flow cytometry
and western blots after synchronising the cells at the G1
phase by double-thymidine block (supplementary mate-
rial, Figure S4A,B). After release from the blockade,
AGS-RV cells progressed from the G1 to the S phase
at 4–6 h, whereas AGS-RN181 cells transited from
the G1 to the S phase at 6–8 h (supplementary mate-
rial, Figure S4A). Cell cycle analyses at the time point
of 6 h (supplementary material, Figure S4C) showed
67.0%± 5.6% of AGS-RN181 cells in the G1 phase ver-
sus 13.0%± 2.2% of AGS-RV control cells in the G1
phase (p < 0.01). In contrast, 16.7%± 3.0% in the S
phase and 16.2%± 1.8% in the G2 phase were observed
for AGS-RN181 versus 79.3%± 6.6% in the S phase
and 7.1%± 1.8% in the G2 phase for AGS-RV, respec-
tively (both p < 0.01). Thus, the results indicate that
RN181 controls the cell cycle transition from G1 to S
phase and compels the GC cells to reside in the G1 phase
for a prolonged period of 2 h.
Cell cycle analyses were also performed for AGS
cells after knockdown of RN181 (supplementary
material, Figure S4B). Compared with up-regulation,
down-regulation of RN181 did not affect the G1–S
phase transition but accelerated DNA synthesis,
shortened the S phase, and promoted the cell cycle
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 1. RN181 is down-regulated and associated with overall survival in GC patients. (A) Representative images of RN181 expressed in GC
tumour samples and adjacent non-tumour tissues examined by IHC. (B) Quantification of IHC scores of RN181 in GC tumour samples and
adjacent non-tumour tissues. The data (mean± SE, n = 165) were analysed by sample-paired t-test. **p < 0.01. (C) Kaplan–Meier survival
analysis comparing GC patients with tumours having high and low expression of RN181. Median survival time of the high expression group
(MSTH > 70.00) versus that of the low expression group (MSTL = 31.92). n = 165; **p < 0.01.
Table 1. Univariate and multivariate Cox regression analysis of potential prognostic factors in 165 gastric cancer patients (HR: hazard
ratio; CI: confidence interval)
Univariate analysis Multivariate analysis
Factors HR 95% CI P value HR 95% CI P value
Gender (male/female) 1.410 0.705–1.659 0.720 1.410 0.887–2.242 0.146
Age (≤ 50/51–70/≥ 71 years) 1.572 1.126–2.196 0.008 1.843 1.303–2.607 0.001
Tumour size (≤ 2.5/2.5–6.5/≥ 6.5 cm) 1.581 1.152–2.170 0.005 1.400 0.990–1.979 0.057
Metastasis (no/yes) 0.373 0.192–0.723 0.004 1.981 0.986–3.981 0.055
Clinical stage (I/II/III/IV) 2.043 1.425–2.929 0.000 1.907 1.285–2.830 0.001
Differentiation (well/moderate/poor) 1.456 0.997–2.125 0.052 1.275 0.845–1.924 0.247
RN181 expression (low/high) 2.246 1.252–4.029 0.007 2.337 1.238–4.411 0.009
transition from S to G2 phase. After the release,
AGS-KD cells progressed from S to G2 phase at
8–10 h, whereas AGS-NC cells transited from S to G2
phase at 10–12 h. Cell cycle distribution analyses at
the time point of 10 h (supplementary material, Figure
S4D) showed 20.7%± 1.7% of AGS-KD in S phase
versus 61.4%± 4.4% of AGS-NC in S phase (p < 0.01).
In contrast, 73.0%± 1.7% in G2 phase was observed for
AGS-KD compared with 32.8%± 4.7% for AGS-NC
(p < 0.01). Thus, the results indicate that knockdown of
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 2. RN181 suppresses tumour growth of GC in vitro and in vivo. (A) Lentivirus-mediated transduction to modulate the expression of
RN181 in AGS cells at mRNA and protein levels as determined by QRT-PCR (left panel) and western blotting (right panel), respectively. (B)
Cell proliferation assays showed that up-regulation of RN181 inhibited the growth (left panel), while down-regulation of RN181 increased
the growth of AGS cells (right panel) in vitro. (C) Colony formation assays showed that up-regulation of RN181 decreased the number of
colonies, whereas down-regulation of RN181 increased the number of colonies formed by AGS cells in vitro. Mean± SD, n = 3. *p < 0.05;
**p < 0.01. (D) Up-regulation of RN181 inhibited tumour growth (top panels), while down-regulation of RN181 promoted tumour growth
(bottom panels) of AGS cells in BALB/c nude mice. The data (mean± SD, n = 6) were analysed by sample-paired t-test. *p < 0.05; **p < 0.01.
(E) IHC and quantification of scoring for RN181, Ki67, and activated caspase 3 on xenograft sections of AGS cells. Original magnification
×10. The data (mean± SD, n = 6) were analysed using Student’s t-test. *p < 0.05; **p < 0.01.
RN181 expedites DNA synthesis, shortens the duration
of the S phase, and promotes the S–G2 phase transition
in GC cell cycles.
RN181 regulates the G1–S transition by decreasing
cyclin D1–CDK4 activity
We investigated the expression of G1/S check-
point core proteins. Up-regulation of RN181
increased the expression of p21 (AGS-RN181 versus
AGS-RV, p < 0.05) but decreased the expression of
cyclin D1, cyclin D3, CDK4, and CDK6 in AGS
cells (AGS-RN181 versus AGS-RV, all p < 0.05)
(Figure 3A). Consistently, down-regulation of RN181
decreased the expression of p21 but increased the
expression of cyclin D1, cyclin D3, CDK4, and CDK6
in AGS cells (AGS-KD versus AGS-NC, all p < 0.05).
Similar results were obtained from MKN28 cells, in
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 3. RN181 regulates the expression of G1/S checkpoint core components. (A) Western blotting analysis and densitometry quantifi-
cation for the expression of RN181, p21, cyclin D1, cyclin D3, CDK4, and CDK6. The data (mean± SD, n = 3) were analysed using Student’s
t-test. *p < 0.05; **p < 0.01. (B) IHC staining and quantification for the expression of RN181, p21, cyclin D1, and CDK4 on tumour sections
of AGS-RN181 versus AGS-RV cells. (C) IHC staining and quantification for the expression of RN181, p21, cyclin D1, and CDK4 on tumour
sections of AGS-KD versus AGS-NC cells. The data (mean± SD, n = 6) were analysed using Student’s t-test. *p < 0.05; **p < 0.01. Original
magnification ×40 (inset ×10). (D) Up-regulation of RN181 reduced the number of tumour cells that have nuclear staining for cyclin D1 and
CDK4 in xenograft tumours of AGS-RN181 versus AGS-RV. (E) Down-regulation of RN181 increased the number of tumour cells showing
nuclear staining for cyclin D1 and CDK4 in xenograft tumours of AGS-KD versus AGS-NC. The data (mean± SD, n = 6) were analysed using
Student’s t-test. *p < 0.05; **p < 0.01.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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which knockdown of RN181 decreased the expression
of p21 but increased the expression of cyclin D1 and
CDK4 (supplementary material, Figure S5A).
To verify the in vitro results, we further investi-
gated the correlation of RN181 expression with the
activities of p21, cyclin D1, and CDK4 in vivo. IHC
staining revealed that up-regulation of RN181 signif-
icantly increased the expression of p21 but dramati-
cally reduced the expression of cyclin D1 and CDK4
in xenograft tumours of AGS cells (AGS-RN181 ver-
sus AGS-RV, all p < 0.01) (Figure 3B). In agreement
with up-regulation, down-regulation of RN181 signif-
icantly decreased the expression of p21 but increased
the expression of cyclin D1 and CDK4 in xenograft
tumours of AGS cells (AGS-KD versus AGS-NC con-
trol, all p < 0.05) (Figure 3C). Similar results were
obtained from xenograft tumours of MKN28 cells in
which RN181 was modulated (supplementary material,
Figure S5B,C).
We also examined the cellular localisation of cyclin
D1 and CDK4. Up-regulation of RN181 dramatically
reduced the percentage of tumour cells that have nuclear
staining for cyclin D1 and CDK4 (AGS-RN181 versus
AGS-RV, p < 0.01) (Figure 3D), while down-regulation
of RN181 significantly increased the percentage of
tumour cells showing nuclear accumulation of cyclin
D1 and CDK4 (AGS-KD versus AGS-NC, p < 0.05)
(Figure 3E). Similar results were obtained from AGS
cells cultured in vitro (supplementary material, Figure
S6). Taken together, the results indicate that RN181 con-
trols the G1–S phase transition by inhibiting the activity
of cyclin D1–CDK4.
Reconstitution of CDK4 rescues the inhibitory
phenotype of GC cells by RN181
We reconstituted the expression of CDK4
in AGS-RN181 cells by adenovirus transductions.
Western blots (Figure 4A) showed that transduction
with pAD-Empty adenovirus did not affect the expres-
sion of either RN181 (RV+Empty versus RV-Empty;
RN181+Empty versus RN181-Empty) or CDK4
(RV+Empty versus RN181+Empty) in AGS cells,
while transduction with pAD-CDK4-His increased
the expression of CDK4 in both AGS-RV control
(RV-CDK4 versus RV+CDK4) and AGS-RN181 cells
(RN181-CDK4 versus RN181+CDK4). Cell prolifera-
tion assays (Figure 4B) confirmed the inhibitory effect
on AGS growth by RN181 (RN181+Empty versus
RV+Empty, p < 0.01). Interestingly, CDK4 reconstitu-
tion not only abolished the growth inhibition by RN181
(RN181+CDK4 versus RN181+Empty, p < 0.01)
but also further increased the cell proliferation of
AGS (RN181+CDK4 versus RV+Empty, p < 0.05),
highlighting a dominant role of CDK4 in control of
the GC growth. However, the increased growth of
AGS-RV cells by CDK4 was much stronger than that
of AGS-RN181 (RV+CDK4 versus RN181+CDK4,
p < 0.01), suggesting that RN181 may also affect other
molecules that regulate GC growth. Similar results were
obtained from colony formation assays (Figure 4C).
We then implantedRN181- andCDK4-overexpressing
cells into nude mice (Figure 4D). Up-regulation
of RN181 significantly inhibited xenograft growth
(RN181 versus RV, p < 0.01). Reconstitution of CDK4
eradicated the growth inhibition in vivo conferred by
RN181 (RN181+CDK4 versus RN181, p < 0.01).
Consistent with the in vitro results, the promotion of
AGS-RV growth in vivo by CDK4 was significantly
greater than that of AGS-RN181 (RV+CDK4 versus
RN181+CDK4, p < 0.01). IHC staining of tumour
sections confirmed the up-regulation of RN181 (RN181
versus RV, p < 0.01) andCDK4 in bothAGS-RV tumour
(RV+CDK4 versus RV, p < 0.01) and AGS-RN181
tumour (RN181+CDK4 versus RN181, p < 0.01)
(Figure 4E).
RN181 suppresses tumour growth by inhibition
of ERK/MAPK in GC cells
We performed RNA-Seq to compare gene expression
profiles in AGS-RN181 cells versus those in AGS-RV
cells. Ingenuity pathway analysis revealed that many
differentially expressed genes regulated by RN181
were integrated in the pathways of ERK1/2–MAPK
and cyclin D (Figure 5A), suggesting that RN181 may
regulate ERK1/2–MAPK signalling which affects the
cyclin D1–CDK4 activity that controls the cell cycle
transition from G1 to S phase.
To address this hypothesis, we first evaluated
the phosphorylation of pERK1/2 in GC cells.
Down-regulation of RN181 significantly increased the
phosphorylation of pERK1/2 in AGS cells both cultured
in vitro (KD versus NC) (Figure 5B) and xenografted
in vivo (KD versus NC, p < 0.01) (Figure 5C). Con-
sistent with the down-regulation results, up-regulation
of RN181 dramatically decreased the phosphorylation
of pERK1/2 (AGS-RN181 versus AGS-RV, p < 0.01).
Similar results were observed in MKN28 cells in which
RN181 was modulated (supplementary material, Figure
S7A,B).
We then treated GC cells with U0126, a highly
selective inhibitor of MEK1/MEK2. Cell proliferation
(Figure 5D) and colony formation (Figure 5E) assays
confirmed that down-regulation of RN181 increased the
abilities of cell growth and colony formation of AGS
cells (AGS-KD versus AGS-NC, p < 0.01). Interest-
ingly, U0126 treatment not only abolished the increased
growth and colony formation abilities of AGS-KD
cells by down-regulation of RN181 (AGS-KD+U0126
versus AGS-KD, p < 0.01) but also decreased the
capacities of cell proliferation and colony formation of
NC-control cells (AGS-NC+U0126 versus AGS-NC,
p < 0.01). Importantly, apart from inhibiting the phos-
phorylation of pERK1/2 in both AGS-KD (KD+U0126
versus KD-U0126) and AGS-NC cells (NC+U0126
versus NC-U0126), U0126 dramatically reduced the
expression of cyclin D1 and CDK4 in both AGS-KD
(KD+U0126 versus KD-U0126) and AGS-NC cells
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 4. Reconstitution of CDK4 rescues the inhibitory phenotype of GC cells by RN181. (A) Western blotting showing the expression of
RN181 and CDK4 in AGS cells. (B) Cell proliferation assays showed that reconstitution of CDK4 increased tumour cell growth of AGS at 24
and 48 h. Mean± SD, n = 3. *p < 0.05; **p < 0.01. (C) Colony formation assays showed that reconstitution of CDK4 increased the colony
numbers produced by AGS. Mean± SD, n = 3. *p < 0.05; **p < 0.01. (D) Tumour growth of AGS cells in BALB/c nude mice. Mean± SD,
n = 6. **p < 0.01. (E) IHC staining and quantification for the expression of RN181 and CDK4 on tumour sections of AGS cells from panel D.
Mean± SD, n = 6. **p < 0.01. Original magnification ×40 (inset ×10).
(NC+U0126 versus NC-U0126) (Figure 5F), suggest-
ing that both cyclin D1 and CDK4 are downstream
targets of ERK/MAPK signalling. Similar results
were observed in MKN28 cells in which RN181 was
modulated (supplementary material, Figure S7C–E).
Taken together, the results indicate that RN181 sup-
presses the tumour growth of GC by inhibition of the
ERK/MAPK pathway and consequently control of the
activity of cyclin D1–CDK4 that regulates the cell cycle
transition from G1 to S phase.
© 2019 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2019
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Figure 5. RN181 suppresses tumour growth by inhibition of ERK/MAPK signalling in AGS cells. (A) Ingenuity pathway analysis of
differentially expressed genes regulated by RN181. (B) Western blotting showing up-regulation of pERK1/2 and cyclin D1 by knockdown
of RN181. (C) IHC staining and quantification for the expression of pERK1/2 on xenograft tumour sections of AGS cells. Mean± SD, n = 6.
**p < 0.01. Original magnification ×40 (inset ×10). (D) In vitro growth curves of AGS cells after knockdown of RN181 and treatment with the
MEK1/2 inhibitor U0126. Mean± SD, n = 3. **p < 0.01. (E) Colony formation assays showing colony numbers produced by AGS cells after
knockdown of RN181 and treatment with U0125. Mean± SD, n = 3. **p < 0.01. (F) Western blotting showing inhibition of the expression
of pERK1/2, cyclin D1, and CDK4 in AGS cells by U0126.
Correlation between RN181 and cyclin D1/CDK4
in GC clinical samples
We further investigated the expression of RN181,
cyclin D1, and CDK4 in GC clinical specimens by IHC
(Figure 6A). Quantitative analysis by scoring the
staining showed that the expression of RN181 was
significantly down-regulated in tumour tissues versus
adjacent non-tumour tissues, while the expression of
cyclin D1 and CDK4 was significantly up-regulated in
tumour tissues versus adjacent tissues, respectively (all
p < 0.001) (Figure 6B). Pearson correlation analyses
revealed that the expression of RN181 was reversely
associated with the levels of cyclin D1 and CDK4,
respectively (all p < 0.001) (Figure 6C). In contrast,
the expression of cyclin D1 was positively correlated
with the expression of CDK4 (p < 0.001) (Figure 6D).
Altogether, the results substantiate the role of the
RN181–cyclin D1/CDK4 pathway in control of the
tumour development of GC.
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Figure 6. Expression and correlation analyses of RN181, cyclin D1, and CDK4 in GC specimens. (A) Representative images of RN181, cyclin
D1, and CDK4 expressed in GC tumour tissue and adjacent non-tumour tissue examined by IHC. (B) Quantification of IHC scoring for
the expression of RN181, cyclin D1, and CDK4 in GC tumour tissue and adjacent non-tumour tissue. The data (mean± SE, n = 75) were
analysed using sample-paired t-test. **p < 0.01. (C) Pearson correlation analysis showing reverse correlations of RN181 expression with the
expression of cyclin D1 and CDK4 in GC tumours, respectively. (D) Pearson correlation analysis showing the positive correlation between
the expression of cyclin D1 and CDK4 in GC tumours.
Discussion
The activation of oncogenes and inactivation of tumour
suppressor genes play major roles in the pathogenesis
of GC [14,15]. Recently, several novel putative tumour
suppressors such as BCL6B [16], CPEB1 [17], ZNF331
[18], ZNF545 [19] and CHIP [20] have been identified
in GC. In this study, we demonstrated that RN181 was
significantly down-regulated in tumour tissues ver-
sus adjacent non-tumour tissues. Remarkably, RN181
expression was inversely associated with tumour dif-
ferentiation, tumour size, clinical stage, and patient’s
overall survival. These results suggest that RN181 may
be involved in the pathogenesis and development of GC
andmay serve as a biomarker for predicting the outcome
of GC patients. To study the possibility that RN181
could affect the carcinogenesis and development of GC,
we modulated the expression of RN181 in GC cells. We
found that up-regulation of RN181 significantly inhib-
ited tumour growth, while down-regulation of RN181
promoted tumour growth by regulation of tumour cell
proliferation and apoptosis in vitro and in vivo. There-
fore, we conclude that RN181 is a novel tumour sup-
pressor in the stomach and controls the tumour growth
of GC.
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on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
Role of RN181 in tumour growth of gastric cancer 11
Many tumour suppressors constrain cell growth
and proliferation by affecting a variety of signalling
pathways that impinge on the core cell-cycle machinery
[14,21]. To explore underlying cellular mechanisms, we
performed cell cycle analyses. Up-regulation of RN181
compelled GC cells to reside in the G1 phase for an extra
2 h, whereas down-regulation of RN181 accelerated
DNA synthesis and increased the cell cycle progression
from the S to the G2 phase for 2 h. Thus, we conclude
that suppression of tumour cell proliferation by RN181
is attributed to the delay of the cell cycle transition from
the G1 to the S phase of GC. Deregulation of signalling
networks during the G1 phase of the cell cycle repre-
sents major driving forces in the tumourigenesis and
development of cancer [21]. Many oncogenes promote
cell proliferation by accelerating the G1–S phase tran-
sition. Cyclin D1, CDK4, and CDK6 are among the
core players for such G1–S phase transition [21–24].
We found that up-regulation of RN181 significantly
decreased the expression of cyclin D1 and CDK4, while
down-regulation of RN181 increased the expression of
cyclin D1 and CDK4 in GC cells. Strikingly, knockdown
of RN181 significantly increased nuclear localisation
of cyclin D1 and CDK4 in tumour cells, suggesting
an increase of cyclin D1–CDK4 activity [22,25,26].
Interestingly, CDK4-deficient MEF cells were reported
to stay in the G1 phase for a prolonged period [27], sug-
gesting that postponement of the G1–S phase transition
may be mediated by decreasing CDK4 expression by
RN181. To corroborate the role of CDK4 in the inhi-
bition of tumour growth by RN181, we reconstituted
the expression of CDK4 in RN181-overexpressing GC
cells. Indeed, CDK4 reconstitution not only rescued
the growth inhibitory phenotype conferred by RN181
both in vitro and in vivo but also further increased the
cell growth and colony formation of GC, highlighting a
dominant role of CDK4 in the control of GC growth by
RN181.
To further investigate underlying mechanisms, we
profiled gene expression by RNA-Seq. We found that
many differentially expressed genes regulated byRN181
were tightly integrated in the pathways of ERK/MAPK
and cyclin D1. In many cell types, both transcription of
cyclin D1 and CDK4 and assembly of cyclin D1 with
CDK4 rely on activation of RAS–RAF–MEK–ERK
signalling [28]. In GC, several factors including the
RAF/MEK/ERK pathway [29] are involved in cyclin D1
up-regulation. We previously found that RN181 could
inhibit the ERK/MAPK pathway in hepatocellular carci-
noma [12]. Therefore, we hypothesised that the suppres-
sion of tumour growth of GC by RN181 may undergo
by reducing the expression and assembly of cyclin D1
with CDK4 mediated by inhibition of ERK/MAPK sig-
nalling in the stomach. Indeed, up-regulation of RN181
significantly inhibited the phosphorylation of pERK1/2
and down-regulation of RN181 greatly increased the
phosphorylation of pERK1/2 in GC cells in vitro and
in vivo. Remarkably, inhibition of MEK/ERK/MAPK
signalling by U0126 not only eliminated the increased
growth of tumour cells by down-regulation of RN181
but also equally decreased the abilities of proliferation
and colony formation of GC cells. More importantly,
U0126 dramatically reduced the expression of cyclin D1
and CDK4, implying that both cyclin D1 and CDK4
are downstream targets of ERK/MAPK signalling in
GC. Tob1, which is known to repress the expression of
cyclin D1 and CDK4 in GC [30], is also phosphory-
lated by ERK/MAPK kinases, which relieves the tran-
scriptional repression of cyclin D1 [31]. ASK1, which
was known to participate in colon and skin tumourigen-
esis, could increase the expression of cyclin D1 through
AP-1 activation and cyclin D1 could up-regulate ASK1
via the Rb-E2F pathway in GC to stimulate tumour
growth [32]. Thus, either Tob1 or ASK1 may also be
involved in the suppression of tumour growth of GC
by RN181.
To verify the results from in vitro and in vivo mod-
els, we further investigated the activity of cyclin D1
and CDK4 in another cohort of GC clinical speci-
mens. We found that the expression of cyclin D1 and
CDK4 was significantly elevated in GC tissues versus
adjacent non-tumour tissues. Indeed, up-regulation of
cyclin D1 and CDK4 was observed in a wide spectrum
of tumours [22,24,26]. Remarkably, about 37–56%
of GC patients expressed abnormally high levels of
cyclin D1 [32–34]. More importantly, the expression
of RN181 was reversely correlated with the expres-
sion of cyclin D1 and CDK4, respectively, while the
expression level of cyclin D1 was positively associated
with the expression of CDK4, highlighting the role of
the RN181–cyclin D1/CDK4 pathway in the tumour
development of GC. Accordingly, we speculate that spe-
cific inhibition of cyclin D1/CDK4 activity may pro-
duce clinical benefits for GC patients who have elevated
expression of cyclin D1 and CDK4 in their tumours.
Importantly, palbociclib, a small-molecule inhibitor of
CDK4 and CDK6, combined with letrozole has recently
been approved to treat postmenopausal women with
ER-positive, HER2-negative advanced breast cancer as
a first-line therapy [35].
In conclusion, we have demonstrated that RN181
is down-regulated in GC and is inversely associated
with some clinicopathological features and patient’s
overall survival. RN181 functions as a tumour sup-
pressor in the stomach to inhibit tumour growth in
vitro and in vivo by control of the cell cycle progres-
sion from G1 to S phase. Mechanistically, RN181
inhibited ERK/MAPK signalling, thereby regulating
cyclin D1–CDK4 activity and consequently con-
trolling the cell cycle progression. Reconstitution of
CDK4 rescued the inhibitory phenotype conferred
by RN181. Importantly, in clinical tumour samples,
RN181 was reversely correlated with the expression
of cyclin D1 and CDK4, highlighting the role of the
RN181–cyclin D1/CDK4 pathway in the control of
tumour growth. Our results provide new insights into
the carcinogenesis and development of GC and facil-
itate the development of novel intervention strategies
against GC by disrupting the ERK/MAPK–cyclin
D1/CDK4 pathway. RN181 may become a
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prognostic biomarker for predicting the outcome of
GC patients.
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